Hubbry Logo
NebivololNebivololMain
Open search
Nebivolol
Community hub
Nebivolol
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Nebivolol
Nebivolol
Nebivolol
View on Wikipedia
from Wikipedia

Nebivolol
Clinical data
Trade namesNebilet, Bystolic, others
Other namesNarbivolol, Nebivolol, Nebivololum[1]
AHFS/Drugs.comMonograph
MedlinePlusa608029
License data
Pregnancy
category
  • AU: C
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding98%
MetabolismLiver (CYP2D6-mediated)
Elimination half-life12-19 hours[3][4][5]
ExcretionKidney and fecal
Identifiers
  • 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)ethanol]
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H25F2NO4
Molar mass405.442 g·mol−1
3D model (JSmol)
  • Fc4cc1c(OC(CC1)C(O)CNCC(O)C3Oc2ccc(F)cc2CC3)cc4
  • InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2 checkY
  • Key:KOHIRBRYDXPAMZ-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Nebivolol is a beta blocker used to treat high blood pressure and heart failure.[6] As with other β-blockers, it is generally a less preferred treatment for high blood pressure.[7] It may be used by itself or with other blood pressure medication.[7] It is taken by mouth.[7]

A bottle of 20mg nebivolol tablets

Common side effects include dizziness, feeling tired, nausea, and headaches.[7] Serious side effects may include heart failure and bronchospasm.[7] Its use in pregnancy and breastfeeding is not recommended.[6][8] It works by blocking β1-adrenergic receptors in the heart and dilating blood vessels.[7][9]

Nebivolol was patented in 1983 and came into medical use in 1997.[10] It is available as a generic medication in the United Kingdom.[6] In 2023, it was the 191st most commonly prescribed medication in the United States, with more than 2 million prescriptions.[11][12]

Medical uses

[edit]

It is used to treat high blood pressure and heart failure.[6] Nebivolol is used in the treatment of angina, to decrease the heart rate and contractile force. This is relevant in patients who need to decrease the oxygen demand of the heart so that the blood supplied from stenosed or constricted arteries is adequate.

ACE inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, and thiazide diuretics are generally preferred over beta blockers for the treatment of primary hypertension in the absence of co-morbidities.[13][14][15][16]

Contraindications

[edit]
  • Severe bradycardia
  • Heart block greater than first degree
  • Patients with cardiogenic shock
  • Decompensated cardiac failure
  • Sick sinus syndrome (unless a permanent pacemaker is in place)
  • Patients with severe hepatic impairment (Child-Pugh class B)
  • Patients who are hypersensitive to any component of this product.

Side effects

[edit]

Side effects might include headache, tiredness, dizziness, lightheadedness, reduced blood flow to extremities, bradycardia.[17]

Interactions

[edit]

Due to enzymatic inhibition, fluvoxamine increases the exposure to nebivolol and its active hydroxylated metabolite (4-OH-nebivolol) in healthy volunteers.[18]

Pharmacology

[edit]

Pharmacodynamics

[edit]

β1-selectivity

[edit]

Beta blockers help patients with cardiovascular disease by blocking β1 receptors, while many of the side-effects of these medications are caused by their blockade of β2 receptors.[19] For this reason, beta blockers that selectively block β1 adrenergic receptors (termed cardioselective or β1-selective beta blockers) produce fewer adverse effects (for instance, bronchoconstriction) than those drugs that non-selectively block both β1 and β2 receptors.

In a laboratory experiment conducted on biopsied heart tissue, nebivolol proved to be the most β1-selective of the β-blockers tested, being approximately 3.5 times more β1-selective than bisoprolol.[20] However, the drug's receptor selectivity in humans is more complex and depends on the drug dose and the genetic profile of the patient taking the medication.[21] The drug is highly cardioselective at 5 mg.[22] In addition, at doses above 10 mg, nebivolol loses its cardioselectivity and blocks both β1 and β2 receptors,[21] while the recommended starting dose of nebivolol is 5 mg, sufficient control of blood pressure may require doses up to 40 mg.[21] Furthermore, nebivolol is also not cardioselective when taken by patients with a genetic makeup that makes them "poor metabolizers" of nebivolol (and other drugs) or with CYP2D6 inhibitors.[21] As many as 1 in 10 Caucasian people and even more black people are poor CYP2D6 metabolizers and therefore might benefit less from nebivolol's cardioselectivity although currently there are no directly comparable studies.[citation needed]

Nebivolol,[23] while selectively blocking beta(1) receptors, acts as a beta(3)-agonist. β3 receptors are found in the gallbladder, urinary bladder, and in brown adipose tissue. Their role in gallbladder physiology is unknown, but they are thought to play a role in lipolysis and thermogenesis in brown fat. In the urinary bladder it is thought to cause relaxation of the bladder and prevention of urination.[24][25][26]

Vasodilator action

[edit]

Nebivolol is unique as a beta-blocker.[27] Unlike carvedilol, it has a nitric oxide (NO)-potentiating, vasodilatory effect via stimulation of β3 receptors.[28][29][30]

Nebivolol induces vasodilation by stimulating the production of nitric oxide, a natural blood vessel relaxant. This effect is achieved by activating the endothelial isoform of NO synthase (eNOS) in the cells lining the blood vessels. Unlike traditional β-blockers, nebivolol's unique mechanism of action improves arterial flexibility and reduces peripheral resistance, making it beneficial for hypertensive patients with endothelial dysfunction. The drug's ability to increase NO production persists even after metabolism, offering long-lasting benefits. Nebivolol's distinct approach to promoting NO release has shown promising results in improving endothelial function and managing hypertension in clinical trials.[31]

Along with labetalol, celiprolol and carvedilol, it is one of four beta blockers to cause dilation of blood vessels in addition to effects on the heart.[30]

Antihypertensive effect

[edit]

Nebivolol lowers blood pressure (BP) by reducing peripheral vascular resistance, and significantly increases stroke volume with preservation of cardiac output.[32] The net hemodynamic effect of nebivolol is the result of a balance between the depressant effects of beta-blockade and an action that maintains cardiac output.[33] Antihypertensive responses were significantly higher with nebivolol than with placebo in trials enrolling patient groups considered representative of the U.S. hypertensive population, in black people, and in those receiving concurrent treatment with other antihypertensive drugs.[34]

Pharmacokinetics

[edit]

Nebivolol's plasma protein binding is approximately 98%, mostly to albumin and its elimination half-life of low doses is 12 hours in extensive CYP2D6 metabolizers and 19 hours in poor metabolizers.[35] It crosses the blood–brain barrier and exerts effects in the central nervous system.[36][37] This may result in central side effects such as depression, insomnia, and nightmares.[36][37]

Chemistry

[edit]

The experimental log P of nebivolol is 4.18 and its predicted log P ranges from 2.44 to 4.21.[38][39][40][41] It is a highly lipophilic beta blocker.[36][41] The drug showed the fourth highest predicted lipophilicity of 30 clinically relevant beta blockers, with the most lipophilic beta blockers predicted to be bopindolol, penbutolol, and carvedilol.[41]

Society and culture

[edit]

Brand names and marketing

[edit]
Ebivol (Nebivolol) tablets.

Mylan Laboratories licensed the US and Canadian rights to nebivolol from Janssen Pharmaceutica N.V. in 2001. Nebivolol is already registered and successfully marketed in more than 50 countries, including the United States where it is marketed under the brand name Bystolic from Mylan Laboratories and Forest Laboratories. Nebivolol is manufactured by Forest Laboratories.

In India, nebivolol is available as Nebula (Zydus Healthcare Ltd), Nebizok (Eris life-sciences), Nebicip (Cipla ltd), Nebilong (Micro Labs), Nebistar (Lupin ltd), Nebicard (Torrent), Nubeta (Abbott Healthcare Pvt Ltd – India), and Nodon (Cadila Pharmaceuticals).

In Greece and Italy, nebivolol is marketed by Menarini as Lobivon.

In Germany it is marketed as Nebilet by Berlin Chemie.

In the Middle East, Russia and Australia, it is marketed under the name Nebilet and in Pakistan it is marketed by The Searle Company Limited as Byscard.

Controversies

[edit]

Tolerability claims

[edit]

Several studies have suggested that nebivolol has reduced typical beta-blocker-related side effects, such as fatigue, clinical depression, bradycardia, or impotence.[42][43][44] However, according to the FDA[45]

Bystolic is associated with a number of serious risks. Bystolic is contraindicated in patients with severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless a permanent pacemaker is in place), severe hepatic impairment (Child-Pugh > B) and in patients who are hypersensitive to any component of the product. Bystolic therapy is also associated with warnings regarding abrupt cessation of therapy, cardiac failure, angina and acute myocardial infarction, bronchospastic diseases, anesthesia and major surgery, diabetes and hypoglycemia, thyrotoxicosis, peripheral vascular disease, non-dihydropyridine calcium channel blockers use, as well as precautions regarding use with CYP2D6 inhibitors, impaired renal and hepatic function, and anaphylactic reactions. Finally, Bystolic is associated with other risks as described in the Adverse Reactions section of its PI. For example, a number of treatment-emergent adverse events with an incidence greater than or equal to 1 percent in Bystolic-treated patients and at a higher frequency than placebo-treated patients were identified in clinical studies, including headache, fatigue, and dizziness.

FDA warning letter about advertising claims

[edit]

In August 2008, the FDA issued a Warning Letter to Forest Laboratories citing exaggerated and misleading claims in their launch journal ad, in particular over claims of superiority and novelty of action.[45]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Nebivolol

View on Grokipedia
from Grokipedia
Nebivolol is a third-generation (beta-blocker) that is highly selective for β1-adrenergic receptors and is used to treat and . Unlike traditional beta-blockers, nebivolol exhibits vasodilatory effects through the release of , which contributes to its favorable hemodynamic profile by reducing peripheral without significantly affecting . Approved by the U.S. in 2007 under the brand name Bystolic and available as a generic since 2021, nebivolol is typically administered orally in tablet form, with dosages ranging from 5 mg to 40 mg daily for (often starting at 5 mg) and up to 10 mg daily for . Its involves competitive antagonism at β1-receptors in the heart, leading to decreased and , while its β3-receptor agonism in endothelial cells promotes production, enhancing and improving endothelial function. This dual action distinguishes it from earlier beta-blockers such as atenolol or metoprolol. Compared with atenolol, nebivolol often shows advantages in regressing left ventricular hypertrophy (LVH) due to its additional vasodilatory effects via nitric oxide release and β3-agonism, leading to better preservation of cardiac output, increased stroke volume, and potentially superior effects on left ventricular remodeling, fibrosis attenuation, and LVH regression. For arrhythmia management (e.g., rate control in atrial fibrillation), both provide similar benefits, with no direct evidence of superiority for one over the other. Nebivolol may also offer benefits in patients with or those at risk for , as it has a neutral or positive impact on lipid profiles and insulin sensitivity. Clinical studies have demonstrated nebivolol's efficacy in lowering and managing symptoms. Overall, nebivolol's profile supports its role as a well-tolerated option in cardiovascular management, particularly for patients requiring alongside beta-blockade.

Medical uses

Hypertension treatment

Nebivolol is indicated for the treatment of in adults, either as monotherapy or in combination with other antihypertensive agents, to lower and thereby reduce the risk of fatal and nonfatal cardiovascular events such as and . The recommended starting dose for is 5 mg orally once daily, with or without food, and may be increased at 2-week intervals up to a maximum of 40 mg once daily based on response. For patients with severe renal impairment ( clearance less than 30 mL/min), the initial dose should be reduced to 2.5 mg once daily, with slow titration if needed; similarly, for moderate hepatic impairment, start at 2.5 mg once daily and titrate slowly, while severe hepatic impairment is a . No specific dose adjustment is required for elderly patients or those with mild renal or hepatic impairment. Clinical trials have demonstrated nebivolol's efficacy in reducing in patients with . In three placebo-controlled, 12-week monotherapy studies involving over 2,000 patients, nebivolol at 5 mg daily produced placebo-subtracted reductions in trough sitting systolic of approximately 6 to 8 mmHg and diastolic reductions of 4 to 6 mmHg, with higher doses (up to 40 mg) achieving greater effects of 7 to 12 mmHg systolic. A trial showed additional lowering when nebivolol (5 to 20 mg) was added to existing regimens, with mean reductions of about 6/4 mmHg. These effects were observed within 2 weeks and sustained over 24 hours. Nebivolol's pharmacological profile includes nitric oxide-mediated vasodilation and beta-3 agonism, distinguishing it from traditional beta-1 selective blockers such as atenolol. Compared to atenolol, nebivolol better preserves cardiac output and increases stroke volume, which may contribute to potentially superior effects on left ventricular hypertrophy regression, attenuation of fibrosis, and improved left ventricular remodeling in patients with hypertension. Long-term studies support nebivolol's sustained efficacy in management, with significant reductions maintained over 6 to 12 months of monotherapy, contributing to overall cardiovascular risk reduction through consistent control.

Heart failure management

Nebivolol is approved in for the treatment of stable mild and moderate chronic specifically in patients over 70 years of age. This indication stems from its demonstrated efficacy in elderly populations, where often presents with comorbidities that necessitate careful drug selection. Patient selection emphasizes those with New York Heart Association (NYHA) class II to IV symptoms, focusing on tolerability in this age group to minimize risks associated with beta-blockade initiation. Dosing for heart failure management begins at 1.25 mg orally once daily, with gradual titration every two weeks by doubling the dose (to 2.5 mg, 5 mg, and up to a maximum of 10 mg daily) based on clinical tolerance and response. This conservative approach allows for monitoring of hemodynamic stability, particularly in elderly patients prone to . The target dose of 10 mg is achieved in approximately 65-70% of patients, prioritizing symptom control and avoidance of excessive . The initial 1.25 mg dose is typically achieved by halving a 2.5 mg tablet, but nebivolol 2.5 mg tablets are unscored and not designed to be split. Splitting them in half (to approximately 1.25 mg) is not recommended, as it can result in uneven and inaccurate dosing, potentially leading to fluctuations in drug effect. While 1.25 mg is within studied dose ranges and may be safe if accurately administered, splitting unscored tablets risks inconsistent dosing. Always consult a healthcare provider before altering doses or splitting tablets; they may recommend a different strength or alternative if a lower dose is needed. The pivotal evidence supporting nebivolol's role in comes from the SENIORS trial, a randomized, double-blind, placebo-controlled study involving 2,128 elderly patients (mean age 76 years) with chronic . The trial demonstrated a 14% in the primary composite endpoint of all-cause mortality or cardiovascular hospitalization (31.1% in the nebivolol group vs. 35.3% in placebo; hazard ratio 0.86, 95% CI 0.74-0.99, p=0.039). This benefit was consistent across subgroups, including those with , and persisted regardless of concurrent use. A key advantage of nebivolol lies in its efficacy among patients with preserved (EF >35%), where subgroup analysis from SENIORS showed similar risk reductions in the primary endpoint compared to those with impaired EF (≤35%). In contrast to non-vasodilating beta-blockers, which have limited evidence of benefit in preserved EF , nebivolol's nitric oxide-mediated vasodilatory properties contribute to improved outcomes in this population. Overall, these findings underscore nebivolol's role in reducing morbidity and mortality in elderly chronic patients, with a favorable tolerability profile during up-titration.

Angina pectoris therapy

Nebivolol is utilized off-label in the management of chronic stable to decrease the frequency of anginal attacks and enhance exercise tolerance. In clinical settings, it helps alleviate ischemic symptoms by modulating cardiac demand during physical activity. The recommended dosing for mirrors that for , starting at 5 mg once daily, with potential titration to 10 mg based on response and tolerability; monitoring is essential to avoid excessive . This regimen supports symptomatic relief without requiring multiple daily administrations. Small-scale clinical trials provide evidence of nebivolol's efficacy in reducing myocardial oxygen demand through reduction, thereby improving anti-ischemic outcomes. For instance, a randomized, placebo-controlled study of 16 patients with stable effort demonstrated that 5 mg daily nebivolol significantly raised the ischemic threshold from 534 seconds to 638 seconds (p < 0.01) and the anginal threshold from 674 seconds to 755 seconds (p < 0.05), while lowering the —a key indicator of oxygen consumption—during exercise. Similarly, an in 20 patients with stable showed that 5-10 mg daily dosing increased exercise duration until onset or 1 mm , alongside significant slowing and reduction, without adverse impacts on left ventricular function. Nebivolol lacks formal approval for pectoris in regions like the and , where its indications are limited to and chronic . However, post-2020 observational data highlight its role in combination regimens, such as with or , for enhanced symptom control in patients with coexisting and stable . These approaches have shown improved exercise stress test performance and reduced clinical symptoms compared to monotherapy. Its blood pressure-lowering effects further aid management by decreasing overall cardiac workload.

Contraindications and precautions

Absolute contraindications

Nebivolol, a beta-adrenergic receptor blocker, is absolutely contraindicated in patients with severe because it can further depress cardiac conduction and exacerbate the risk of life-threatening arrhythmias or . Similarly, it is prohibited in individuals with greater than first degree in the absence of a functioning pacemaker, as the drug's negative and effects may worsen conduction disturbances, potentially leading to complete or hemodynamic instability. The medication must not be used in cases of , , or , where beta-blockade could intensify myocardial depression, reduce cardiac output, and precipitate acute or circulatory collapse, consistent with class-wide risks of beta-blockers in acutely unstable cardiac states. It is also contraindicated in patients with sick sinus syndrome (unless a permanent pacemaker is in place). Additionally, nebivolol is contraindicated in acute or chronic severe hepatic impairment (Child-Pugh class C), owing to significantly impaired via the CYP2D6 pathway, resulting in unpredictable and heightened toxicity risk. Finally, known to nebivolol or any of its excipients represents an absolute , as administration could trigger severe allergic reactions, including , in sensitized patients.

Special precautions

Nebivolol requires dose adjustments in patients with hepatic or renal impairment to account for altered . In individuals with moderate hepatic impairment (Child-Pugh class B), the recommended initial dose is 2.5 mg once daily, with slow if needed, due to decreased of the drug. For severe renal impairment ( clearance less than 30 mL/min), the initial dose is also reduced to 2.5 mg once daily, as renal clearance of nebivolol is diminished in such cases. No dose adjustment is typically necessary for mild hepatic impairment or mild to moderate renal impairment. Patients with diabetes mellitus should use nebivolol with caution, as beta-blockers like nebivolol may mask certain signs of , such as , particularly in those on insulin or oral hypoglycemic agents. Close monitoring of blood glucose levels is advised in this population to detect hypoglycemic episodes early. In perioperative settings, nebivolol should generally be continued in patients already receiving beta-blockers to prevent risks associated with abrupt withdrawal, such as exacerbation of or increased incidence. If discontinuation is necessary, gradual tapering over one to two weeks is recommended to avoid rebound or other cardiovascular events. Nebivolol should not be used during pregnancy unless strictly necessary, due to its pharmacological properties that may cause harmful effects on the pregnancy and/or the fetus/newborn. Beta-blockers reduce placental perfusion, potentially leading to intrauterine growth retardation, intrauterine death, abortion, or premature labor. Adverse effects on the fetus and newborn may include hypoglycemia and bradycardia. If beta-blocker treatment is necessary, preference should be given to a beta-1 selective blocker. If treatment with nebivolol is deemed necessary, uteroplacental blood flow and fetal growth should be monitored. In case of harmful effects on the pregnancy or fetus, alternative treatment should be considered. The newborn should be closely monitored for symptoms of hypoglycemia and bradycardia, which typically occur in the first 3 days of life. Breastfeeding is not recommended in mothers taking nebivolol, as animal studies have shown that nebivolol is excreted in breast milk, and although excretion in human milk is unknown, most beta-blockers pass into breast milk to varying degrees. A risk to the breastfed infant cannot be excluded, and serious adverse reactions such as bradycardia may occur. Discontinuation of nursing or nebivolol should be considered based on the importance of the therapy to the mother.

Adverse effects

Common side effects

The most common side effects of nebivolol, observed in placebo-controlled clinical trials for involving over 1,500 patients, include , , and . occurs in 6% to 9% of patients, typically mild and transient. affects 2% to 4%, often related to postural changes, while is reported in 2% to 5%, with higher rates at doses of 20 to 40 mg daily. Cardiovascular side effects such as bradycardia (slow heart rate) are also common, occurring in up to 11% of patients, particularly at higher doses. Shortness of breath (dyspnea) affects 1% to 10% of patients. Peripheral effects like cold hands and feet may occur due to reduced blood flow. Gastrointestinal side effects are less frequent but notable, with occurring in 1% to 3% and in approximately 2% of patients. These incidences are derived from three 12-week monotherapy trials comparing nebivolol (doses of 5 to 40 mg) to . A of 12 clinical trials confirmed significantly fewer adverse events with nebivolol compared to other antihypertensive agents, including traditional beta-blockers (odds ratio 0.59), attributable in part to its vasodilatory profile mediated by release. Management of these mild side effects generally involves , such as over-the-counter analgesics for or rest for , with most resolving as the body adjusts. If symptoms persist or interfere with daily activities, dose reduction or adjustment under medical supervision may be recommended to maintain while minimizing discomfort.

Serious adverse effects

Nebivolol, like other beta-blockers, can cause , atrioventricular (AV) block, or worsening , with occurring in approximately 1% of patients at higher doses (20-40 mg) in clinical trials. These cardiac effects typically require monitoring of and symptoms of , particularly in patients with pre-existing cardiac conditions. Despite its beta-1 selectivity, nebivolol may induce in susceptible patients with , leading to acute respiratory distress that necessitates discontinuation and therapy. Post-marketing surveillance has identified additional serious risks, including impotence or , allergic reactions such as or , and acute renal failure. These events are rare, with incidences not reliably estimable due to voluntary reporting, but they underscore the need for prompt medical evaluation. Although some reports associate beta-blockers with depression, analyses of large-scale randomized controlled trials as of 2021 do not support a causal link. Nebivolol has no diuretic effect and is not associated with changes in urination, urine output, or urinary frequency as common side effects. Decreased urine output has been reported as a rare adverse effect or in overdose scenarios. Abrupt withdrawal of nebivolol carries significant risks, including exacerbation of , , or ventricular arrhythmias, as highlighted in the drug's warnings; gradual tapering over 1-2 weeks is recommended to mitigate these dangers. Overlaps with contraindications, such as severe or decompensated , emphasize the importance of careful patient selection.

Drug interactions

Pharmacokinetic interactions

Nebivolol undergoes extensive hepatic metabolism primarily via the enzyme, making its susceptible to alterations by CYP2D6 inhibitors and genetic polymorphisms in this enzyme. Potent CYP2D6 inhibitors, such as and , significantly elevate nebivolol plasma concentrations by reducing its metabolism. Co-administration with , for instance, increases the area under the curve (AUC) of the active d-nebivolol isomer by up to 8-fold and the maximum plasma concentration (Cmax) by 3-fold. Similar caution is advised with , as it can substantially raise nebivolol exposure, potentially necessitating dose reduction. Genetic variability in activity further influences nebivolol , with poor metabolizers—comprising 7-10% of Caucasians—exhibiting markedly higher drug exposure due to reduced clearance. In these individuals, the of d-nebivolol can reach up to 96%, compared to approximately 12% in extensive metabolizers, and the elimination extends to about 19 hours versus 12 hours. Nebivolol is also subject to minor metabolism by CYP3A4, where strong inhibitors like ketoconazole can decrease its clearance and thereby increase systemic exposure. Nebivolol has no significant pharmacokinetic interactions with olmesartan, as olmesartan undergoes non-CYP-mediated hydrolysis during absorption and does not interact with CYP2D6 or CYP3A4. Unlike some beta-blockers, nebivolol shows no clinically significant pharmacokinetic interactions with food, permitting administration regardless of meals, though minor reductions in certain metabolites may occur under fed conditions. Steady-state plasma levels are generally attained within 3-5 days in extensive and poor metabolizers, respectively, with about 1.5-fold accumulation upon repeated once-daily dosing.

Pharmacodynamic interactions

Nebivolol, as a beta-1 selective blocker, can engage in pharmacodynamic interactions with other medications that modulate cardiovascular or metabolic responses, potentially amplifying therapeutic effects or risks at the receptor or physiological level. When coadministered with other antihypertensive agents, nebivolol may produce additive reductions in and , necessitating careful monitoring to avoid excessive or . Specifically, no significant pharmacodynamic interactions beyond expected additive antihypertensive effects have been reported with olmesartan, an angiotensin II receptor blocker, making combination therapy safe and effective for hypertension management; however, monitoring for bradycardia is recommended due to nebivolol's heart rate-lowering effects (e.g., reduction from approximately 74 to 70 bpm observed in studies), while olmesartan does not significantly affect heart rate. In patients with acute ischemic stroke, both nebivolol and olmesartan similarly reduce brachial and aortic blood pressure and improve arterial stiffness, but only nebivolol significantly lowers heart rate. Specifically, combination with such as verapamil or can exacerbate myocardial depression, leading to profound decreases in , , and cardiac contractility, as well as potential AV conduction disturbances; electrocardiographic and hemodynamic monitoring is recommended in such cases. In patients with managed by insulin or , nebivolol can mask early warning signs of , particularly , due to its beta-1 blocking action, thereby increasing the risk of unrecognized or severe hypoglycemic episodes. This interaction may also prolong , especially in fasting states, requiring vigilant and on alternative symptoms like diaphoresis or . Nonsteroidal anti-inflammatory drugs (NSAIDs) may diminish nebivolol's antihypertensive efficacy by inhibiting renal synthesis, which promotes sodium retention, , and reduced , thereby counteracting lowering. This effect is more pronounced with chronic NSAID use, and should be reassessed during concurrent . Alcohol consumption can potentiate the depressant effects of nebivolol, resulting in enhanced dizziness, sedation, and due to additive impacts on tone and psychomotor function. Patients are advised to limit or avoid alcohol to mitigate these risks.

Pharmacodynamics

Nebivolol acts primarily as a highly selective β1-adrenergic , exhibiting approximately 300-fold greater affinity for β1 receptors compared to β2 receptors, which contributes to its cardioselectivity at therapeutic doses. This selectivity minimizes effects on β2-mediated functions such as bronchodilation and , distinguishing it from less selective beta-blockers. By blocking β1 receptors in the heart, nebivolol reduces and , thereby decreasing . Nebivolol is a of (d)- and (l)-s, with the (d)- responsible for β1-receptor antagonism and the (l)- mediating β3-receptor . In addition to its β1-antagonistic properties, nebivolol promotes through the release of (NO) from vascular , a mechanism independent of its beta-blockade effects. This NO-mediated action is facilitated by nebivolol's at β3-adrenergic receptors on endothelial cells, leading to of endothelial (eNOS) and subsequent relaxation of vascular . The resulting decrease in peripheral enhances nebivolol's antihypertensive efficacy, particularly in patients with . The combined effects of reduced and peripheral underlie nebivolol's blood pressure-lowering action. Unlike traditional beta-blockers, nebivolol demonstrates minimal adverse impact on profiles or insulin sensitivity, often showing neutral or even beneficial effects due to its NO-enhancing properties, which may improve metabolic parameters in hypertensive patients. Compared to traditional β1-selective beta-blockers such as atenolol, nebivolol's additional β3-agonism and NO-mediated vasodilation enable blood pressure reduction with better preservation of cardiac output and an increase in stroke volume, as opposed to atenolol's greater reliance on reductions in heart rate and contractility. These hemodynamic advantages may contribute to improved left ventricular remodeling, attenuation of myocardial fibrosis, and potentially superior regression of left ventricular hypertrophy through enhanced endothelial function and reduced myocardial stress.

Pharmacokinetics

Nebivolol is administered orally and exhibits low absolute bioavailability of approximately 12% in extensive metabolizers (EMs) due to extensive first-pass metabolism in the liver, while poor metabolizers (PMs) achieve nearly complete bioavailability of about 96%. Peak plasma concentrations are reached within 1.5 to 4 hours after dosing, and food does not significantly alter its absorption profile. The drug is highly bound to plasma proteins, approximately 98%, primarily to , with binding independent of concentration. Its averages 10 L/kg, reflecting extensive tissue distribution. Nebivolol undergoes extensive hepatic metabolism primarily through -mediated oxidation to form active hydroxyl metabolites, alongside direct and N-dealkylation pathways; these metabolites contribute to its β-blocking activity. The elimination varies significantly by CYP2D6 phenotype, ranging from 10 to 12 hours in EMs to 19 to 32 hours in PMs, leading to potential differences in dosing considerations for pharmacokinetic interactions. Excretion occurs mainly via nonrenal routes in EMs, with about 44% eliminated in (primarily biliary) and 38% in , whereas PMs show predominantly renal elimination at 67% in and only 13% in . Less than 1% of the dose is excreted as unchanged in either group.

Chemistry

Chemical structure and properties

Nebivolol has the molecular formula \ceC22H25F2NO4\ce{C22H25F2NO4} and a molecular weight of 405.44 g/mol. Its features two 6-fluoro-3,4-dihydro-2H-chromen-2-yl (6-fluoro chroman-2-yl) moieties linked by a 2-[(2-hydroxy-1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethyl)amino]ethanol bridge, incorporating fluoro substituents at the 6-position of each chromane ring and an amino alcohol linkage. This arrangement contributes to its classification as a third-generation beta-blocker with a distinct molecular scaffold derived from chromane. Nebivolol , the pharmaceutical form, is a white to almost white powder that is very slightly soluble in , sparingly soluble in , , and 400, and soluble in , , and N,N-dimethylformamide. It is practically insoluble in acetone, ethyl acetate, , , , and . These properties influence its formulation into oral tablets, requiring excipients to enhance . Nebivolol is utilized as a comprising equal proportions of its d-(SRRR) and l-(RSSS) enantiomers, with the d-enantiomer primarily responsible for β1-blockade activity and the l-enantiomer for nitric oxide-mediated . The molecule possesses multiple chiral centers, resulting in stereoisomers that exhibit differential biological profiles, though the racemate is the standard therapeutic form.

Synthesis and formulation

Nebivolol is synthesized through a multi-step process involving N-alkylation of a primary with enantiomerically enriched 6-fluoro-chroman-2-yl oxiranes, followed by deprotection, as patented by Janssen Pharmaceutica (EP 0145067). The process emphasizes stereoselective coupling to achieve the desired diastereomers, with overall yields typically 20-30% over 8-10 steps. Pharmaceutically, nebivolol is formulated as the salt to enhance stability and solubility, available in tablet strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg of nebivolol base. These oral tablets are film-coated to mask any bitter taste and improve swallowability. Excipients vary by region, brand, and manufacturer. In US formulations, excipients typically include monohydrate for bulk, croscarmellose sodium as a disintegrant, for compression, and as a , with colorants like FD&C Yellow No. 6 aluminum lake used in the 5 mg tablets for identification. In the French/European TEMERIT 5 mg formulation, excipients are polysorbate 80 (E433), hypromellose (E464), lactose monohydrate, maize starch, croscarmellose sodium (E468), microcrystalline cellulose (E460), colloidal anhydrous silica (E551), and magnesium stearate (E470b). These formulations ensure consistent bioavailability with over 90% absorption in the .

History

Development and discovery

Nebivolol was discovered in the early by researchers at Janssen Pharmaceutica in as part of efforts to develop a novel third-generation beta-blocker with enhanced cardioselectivity and vasodilatory properties. In 2001, Laboratories licensed the and Canadian rights to nebivolol from Janssen Pharmaceutica. The compound, chemically known as α,α'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol], emerged from synthetic work on derivatives of 2,2'-iminobisethanol aimed at treating coronary-vascular disorders. The invention was patented under US Patent 4,654,362, filed on October 12, 1984, and issued on March 31, 1987, emphasizing the compound's β1-selectivity combined with (NO)-mediated to improve endothelial function beyond traditional beta-blockers. This dual mechanism was designed to mitigate the vasoconstrictive side effects observed with earlier agents like atenolol. Preclinical studies in animal models, including isolated tissues and hypertensive rats, demonstrated nebivolol's superior endothelial effects, such as enhanced NO production leading to , compared to atenolol, which lacked similar NO-potentiating activity. For instance, in coronary microvessels, nebivolol induced endothelium-dependent hyperpolarization and NO release, reducing peripheral resistance without the reflex seen in non-vasodilatory beta-blockers. Initially formulated as salt for , the compound showed favorable in early pharmacokinetic evaluations in animals, supporting its advancement to clinical development.

Regulatory approvals and updates

Nebivolol received approval from the U.S. (FDA) on December 17, 2007, for the treatment of in adults. This approval was based on clinical trials demonstrating its efficacy in reducing through beta-1 selective blockade and nitric oxide-mediated . The drug is marketed in the United States under the brand name Bystolic and is available in tablet strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg. In the , nebivolol has been authorized nationally for since the mid-1990s, with initial marketing in countries like the in 1995; it came into medical use in 1997. The later supported its use for stable mild to moderate chronic in patients aged 70 years or older, based on evidence from the SENIORS trial, which showed a reduction in all-cause mortality or cardiovascular hospitalization. This indication was incorporated into product labels across EU member states by the late . By 2006, nebivolol was available in more than 70 countries worldwide. Generic versions have become available in markets like the since 2021, and there have been patent litigations over nebivolol formulations into the 2010s. In , the brand Nebaloc (nebivolol hydrochloride) was registered by the (TGA) on February 18, 2025, for the treatment of and as adjunctive therapy in stable chronic for patients aged 70 years or older. This registration aligns with global standards and includes formulations of 5 mg and 10 mg tablets in blister packs. A key label update occurred in 2010, when the FDA revised the prescribing information for Bystolic to address in CYP2D6 poor metabolizers. The update clarified that no dose adjustments are required for this population, as the clinical effects and safety profile remain comparable to extensive metabolizers, despite prolonged exposure due to reduced . This change was informed by pharmacogenetic studies highlighting nebivolol's stereoselective primarily via . Subsequent label revisions have focused on minor safety communications, such as interactions and post-marketing surveillance, with no major expansions or withdrawals as of November 2025.

Society and culture

Brand names and marketing

Nebivolol is marketed under the primary brand name Bystolic in the United States by (which acquired , formerly ). Internationally, it is available under various brand names, including Nebilet in , Nebicard in , and Lobivon in . The drug is promoted as a third-generation beta-blocker, highlighting its high selectivity for beta-1 receptors combined with nitric oxide-mediated vasodilatory effects, which contribute to improved tolerability compared to earlier generations. Marketing strategies emphasize its favorable side effect profile, including lower incidences of and , making it suitable for a broader patient population. A key promotional feature is its once-daily dosing regimen, typically starting at 5 mg, which supports patient adherence and sustains 24-hour control. In the United States, Bystolic enjoyed patent exclusivity until December 17, 2021, after which generic versions entered the market, significantly enhancing accessibility and reducing costs for patients.

Availability and prescriptions

Nebivolol is available exclusively as a prescription worldwide and is not sold over-the-counter in any country. , nebivolol ranked as the 191st most commonly prescribed in 2023, with over 2.5 million prescriptions dispensed annually. Following the expiration of the brand-name Bystolic in 2021, generic versions have dominated the market, comprising the majority of prescriptions. The cost of generic nebivolol is significantly lower than the branded version, typically ranging from $10 to $20 per month for a standard supply, compared to over $100 for the brand-name equivalent without . Most plans in the cover nebivolol, often with low copayments for generics, making it accessible for patients managing or . Usage of nebivolol is higher in developed markets such as the and , where it benefits from established regulatory approvals and widespread physician familiarity. In emerging Asian markets, adoption has grown since 2020, driven by increasing approvals and clinical studies demonstrating efficacy in local populations, though it remains less prevalent than in Western countries due to preferences for other beta-blockers.

Controversies

In August 2008, the U.S. (FDA) issued a warning letter to regarding promotional advertisements for Bystolic (nebivolol) in professional journals, citing multiple violations of the Federal Food, Drug, and Cosmetic Act. The agency determined that the materials misleadingly presented nebivolol as a "novel, next generation " with a "unique mechanism" involving cardioselective beta blockade and , implying superiority over other beta-blockers without substantial evidence from adequate and well-controlled studies. Additionally, claims of efficacy "demonstrated across a broad range of patients," including obese individuals, poor metabolizers, and diabetics, were unsubstantiated, as no specific clinical trials supported these subgroups. The advertisements also omitted critical risk information, such as cautions for use in compensated congestive and drug interactions with inhibitors like , which can increase nebivolol exposure up to eightfold. A key element of the controversy centered on unsubstantiated tolerability claims, such as the assertion of a "favorable tolerability profile with a low incidence of beta blocker-related side effects," which implied better tolerability than existing agents without comparative data. This sparked debates regarding the alignment of promotional statements with clinical evidence, particularly in comparisons to other beta-blockers like . Studies evaluating both drugs in patients with chronic and reduced left ventricular systolic function have shown similar improvements in left ventricular function, exercise capacity, and overall safety profiles, with no clear evidence of nebivolol's superiority in tolerability. For instance, both agents demonstrated comparable reductions in and while maintaining hemodynamic benefits, though some analyses indicated potentially higher discontinuation rates with in long-term follow-up. These findings underscored criticisms that ' marketing exaggerated nebivolol's advantages beyond what trial data supported. Post-marketing surveillance of nebivolol has raised questions about the long-term sustainability of its (NO)-mediated vasodilatory effects, particularly in diverse populations where initial clinical trials underrepresented non-Caucasian groups. While pre-approval data suggested NO release as a key mechanism, with small human studies indicating potential benefits, the exact pathway remained unclear, prompting ongoing scrutiny in real-world use. A targeted study in high-risk, obese African American patients with stage 1 found that nebivolol improved NO bioavailability and vascular function alongside reductions, addressing some gaps in diverse cohorts. However, broader post-marketing data, including analyses, highlight the need for extended monitoring to confirm these effects' durability and safety across ethnicities, given limited long-term evidence beyond predominantly white populations. The introduction of generic nebivolol faced significant delays due to patent litigation and settlement agreements between (later acquired by ) and generic manufacturers, restricting market entry until September 2021 despite earlier filings dating back to 2012. These reverse payment settlements, in which generics agreed to delay in exchange for licenses, were challenged in antitrust lawsuits by direct and indirect purchasers, alleging they unlawfully maintained Bystolic's monopoly and inflated prices. Courts examined these arrangements under the Hatch-Waxman Act, but the claims were dismissed by the U.S. Court of Appeals for the Second Circuit in May 2024.

References

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021742s013lbl.pdf
  2. https://go.drugbank.com/drugs/DB04861
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC2697096/
  4. https://pubmed.ncbi.nlm.nih.gov/20030424/
  5. https://www.drugs.com/availability/generic-bystolic.html
  6. https://www.ncbi.nlm.nih.gov/books/NBK551582/
  7. https://pubmed.ncbi.nlm.nih.gov/19443516/
  8. https://pubmed.ncbi.nlm.nih.gov/12888152/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC5348202/
  10. https://pubmed.ncbi.nlm.nih.gov/18447840/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC4541699/
  12. https://pubmed.ncbi.nlm.nih.gov/26177892/
  13. https://pubmed.ncbi.nlm.nih.gov/9990650/
  14. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021742s028lbl.pdf
  15. https://www.nature.com/articles/jhh20178
  16. https://www.tandfonline.com/doi/full/10.2217/fca-2021-0048
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC2291309/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC8720793/
  19. https://academic.oup.com/eurheartj/article/26/3/215/2888055
  20. https://pubmed.ncbi.nlm.nih.gov/15642700/
  21. https://www.sciencedirect.com/science/article/pii/S0735109709009875
  22. https://pubmed.ncbi.nlm.nih.gov/12494203/
  23. https://link.springer.com/article/10.1007/BF03258269
  24. https://www.medicines.org.uk/emc/product/9992/smpc
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC9737178/
  26. https://academic.oup.com/eurheartj/article/34/suppl_1/P4002/2862149
  27. https://www.rxabbvie.com/pdf/bystolic_pi.pdf
  28. https://reference.medscape.com/drug/bystolic-nebivolol-342363
  29. https://base-donnees-publique.medicaments.gouv.fr/medicament/67113350/extrait
  30. https://www.drugs.com/sfx/nebivolol-side-effects.html
  31. https://myhealth.alberta.ca/Health/medications/pages/conditions.aspx?hwid=fdb1072
  32. https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.16590
  33. https://www.mayoclinic.org/drugs-supplements/nebivolol-oral-route/side-effects/drg-20071459
  34. https://www.ncbi.nlm.nih.gov/books/NBK574601/
  35. https://go.drugbank.com/drugs/DB00275
  36. https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/BYSTOLIC_PM_EN.pdf
  37. https://www.drugs.com/drug-interactions/nebivolol-with-olmesartan-2788-0-1745-0.html
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC6800900/
  39. https://www.acpjournals.org/doi/10.7326/0003-4819-121-4-199408150-00011
  40. https://pubmed.ncbi.nlm.nih.gov/9397294/
  41. https://www.drugs.com/drug-interactions/alcohol-contained-in-alcoholic-beverages-with-nebivolol-1034-14582-2788-0.html
  42. https://www.healthline.com/health/drugs/nebivolol-oral-tablet
  43. https://www.jacc.org/doi/10.1016/j.jacc.2009.05.066
  44. https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.111.189589
  45. https://www.geneesmiddeleninformatiebank.nl/pars/h33885.pdf
  46. https://pubchem.ncbi.nlm.nih.gov/compound/Nebivolol
  47. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ChemR.pdf
  48. https://pubmed.ncbi.nlm.nih.gov/18485134/
  49. https://patents.google.com/patent/EP0145067B1/en
  50. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=202d5142-6180-4d48-9a9f-1bd6992fc49b
  51. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_MedR_P10.pdf
  52. https://adisinsight.springer.com/drugs/800000191
  53. https://patents.google.com/patent/US4654362A/en
  54. https://www.ahajournals.org/doi/10.1161/01.cir.102.6.677
  55. https://www.ahajournals.org/doi/10.1161/circulationaha.105.556233
  56. https://europepmc.org/article/med/2455841
  57. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000TOC.cfm
  58. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_MedR_P1.pdf
  59. https://db.cbg-meb.nl/pars/h35175.pdf
  60. https://www.drugs.com/international/nebivolol.html
  61. https://cardiovascularbusiness.com/topics/clinical/structural-heart-disease/fda-panel-votes-down-bystolic-heart-failure-treatment
  62. https://www.jpml.uscourts.gov/sites/jpml/files/MDL-2364-Initial_Transfer-05-12.pdf
  63. https://www.tga.gov.au/resources/artg/431972
  64. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021742s007lbl.pdf
  65. https://www.bystolic.com/
  66. https://pubmed.ncbi.nlm.nih.gov/19393838/
  67. https://www.fiercepharma.com/special-report/top-10-drugs-losing-u-s-exclusivity-2021
  68. https://www.mayoclinic.org/drugs-supplements/nebivolol-oral-route/description/drg-20071459
  69. https://clincalc.com/DrugStats/Drugs/Nebivolol
  70. https://www.medicalnewstoday.com/articles/drugs-nebivolol-cost
  71. https://www.goodrx.com/nebivolol
  72. https://journals.lww.com/jhypertension/fulltext/2020/03000/real_world_efficacy_and_safety_of_nebivolol_in.23.aspx
  73. https://www.maiaresearch.com/market-report/1024260-Nebivolol-Hydrochloride-1024260.html
  74. https://cdn.mdedge.com/files/s3fs-public/issues/articles/70098_main_21.pdf
  75. https://pubmed.ncbi.nlm.nih.gov/16290981/
  76. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.01212/full
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC3746509/
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC10864489/
  79. https://law.justia.com/cases/federal/appellate-courts/ca2/23-410/23-410-2024-05-13.html
Add your contribution
Related Hubs
User Avatar
No comments yet.